Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Ohio Health Panel Hears Personal Stories and Cost Data as It Considers Mandated Coverage for Biomarker Tests
Summary
At a second hearing on House Bill 8, clinicians, patient advocates and industry groups urged the Ohio House Health Committee to require state-regulated plans and Medicaid to cover guideline‑indicated biomarker testing, citing patient stories, clinical benefit and actuarial analyses of modest premium impact.
The Ohio House Health Committee heard hours of testimony supporting House Bill 8 on biomarker testing coverage, with doctors, survivors and industry representatives telling personal stories and offering data they say show the tests improve treatment selection and can lower downstream costs.
Supporters described cases in which biomarker testing changed treatment and outcomes. Reagan Mammott, an assistant professor and thoracic medical oncologist at The Ohio State University Comprehensive Cancer Center — James, said biomarker testing “determines the best treatment for a person's cancer” and recounted a patient with an ALK driver mutation who avoided ineffective immunotherapy and saw “nearly complete resolution of his cancer” within two months after targeted therapy.
Proponents framed the bill as narrowly targeted to guideline‑indicated use. Leo Almeida, government relations director for the…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
